Cellosaurus logo
expasy logo

Cellosaurus DSH1 (CVCL_1182)

[Text version]
Cell line name DSH1
Accession CVCL_1182
Resource Identification Initiative To cite this cell line use: DSH1 (RRID:CVCL_1182)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Japanese.
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
Sequence variations
  • Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg158His (c.473G>A); ClinVar=VCV000141963; Zygosity=Homozygous (Cosmic-CLP=753552; DepMap=ACH-002235).
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.74
Native American0
East Asian, North71.8
East Asian, South26.84
South Asian0
European, North0
European, South0.61
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling 48Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP=753552

Markers:
AmelogeninX,Y
CSF1PO12
D5S81811
D7S8209,11
D13S3178,10
D16S53910,12
TH019
TPOX8,9
vWA16,17

Run an STR similarity search on this cell line
Publications

PubMed=11921286; DOI=10.1002/gcc.10050
Williams S.V., Sibley K.D., Davies A.M., Nishiyama H., Hornigold N., Coulter J., Kennedy W.J., Skilleter A., Habuchi T., Knowles M.A.
Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines.
Genes Chromosomes Cancer 34:86-96(2002)

PubMed=15846775; DOI=10.1002/gcc.20166
Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J.M., Knowles M.A.
Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro.
Genes Chromosomes Cancer 43:315-328(2005)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=24367658; DOI=10.1371/journal.pone.0084411; PMCID=PMC3867501
Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H., Knowles M.A.
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
PLoS ONE 8:E84411-E84411(2013)

PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057
Hurst C.D., Platt F.M., Knowles M.A.
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Eur. Urol. 65:367-369(2014)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line databases/resources CLO; CLO_0037158
cancercelllines; CVCL_1182
Cell_Model_Passport; SIDM00970
Cosmic-CLP; 753552
DepMap; ACH-002235
LINCS_LDP; LCL-1706
Chemistry resources ChEMBL-Cells; CHEMBL3308520
ChEMBL-Targets; CHEMBL2366079
GDSC; 753552
PharmacoDB; DSH1_308_2019
PubChem_Cell_line; CVCL_1182
Encyclopedic resources Wikidata; Q54831450
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-3610
GEO; GSM1669744
Polymorphism and mutation databases Cosmic; 753552
Cosmic; 1046688
Cosmic; 1175826
Cosmic; 1285116
Cosmic; 1285991
Cosmic; 2050441
Cosmic; 2057445
Cosmic; 2444226
Cosmic; 2685943
IARC_TP53; 21312
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number36